Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nucleic-acid therapeutics: basic principles and recent applications.

Joanna B Opalinska1, Alan M Gewirtz

  • 1Department of Hematology, Pommeranian Academy of Medicine, Ul Rybacka 1, 71-252 Szczecin, Poland.

Nature Reviews. Drug Discovery
|July 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.

Blood advances·2025
Same author

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.

The Lancet. Haematology·2025
Same author

Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.

Blood cancer journal·2025
Same author

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.

Blood cancer journal·2025
Same author

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.

Blood cancer journal·2019
Same author

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.

The Lancet. Oncology·2018

Novel nucleic acid therapies, including antisense oligonucleotides and ribozymes, offer promising strategies for blocking abnormal gene expression. These advanced therapeutics are revolutionizing disease treatment, with some already approved and others in clinical trials.

Area of Science:

  • Molecular Biology
  • Genetics
  • Pharmacology

Background:

  • Human genome sequencing and pathway elucidation offer new therapeutic development avenues.
  • Emerging molecular therapeutics include antisense oligonucleotides and ribozymes.
  • These nucleic acid technologies target abnormal gene expression.

Purpose of the Study:

  • To review strategies for modulating gene expression using nucleic acid therapies.
  • To discuss the successes and challenges of gene expression modulation therapies.

Main Methods:

  • Review of existing literature on antisense technology and ribozymes.
  • Analysis of FDA-approved nucleic acid therapies.
  • Examination of ongoing clinical trials for nucleic acid-based treatments.

Related Experiment Videos

Main Results:

  • Antisense technology and ribozymes are effective tools for blocking abnormal gene expression.
  • One antisense drug is approved for cytomegalovirus retinitis.
  • Multiple nucleic acid therapies are in clinical development.

Conclusions:

  • Nucleic acid therapies represent a significant advancement in targeted drug development.
  • Continued research and clinical trials are essential for realizing the full potential of these therapies.
  • Addressing challenges is key to the successful clinical application of gene expression modulation.